Pharmaceutical Technology on MSN13 天
EC approves Bristol Myers Squibb’s follicular lymphoma CAR T therapy
The European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...
The Pharma Letter13 天
EC expands use of CAR T cell therapy Breyanzi
The European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric ...
The Pharma Letter10 天
Chugai launches Lunsumio in Japan for follicular lymphoma
Chugai Pharmaceutical has launched Lunsumio (mosunetuzumab) in Japan for patients with relapsed or refractory follicular ...
Canadian Medical Association Journal6 天
Advanced folliculotropic mycosis fungoides in a 66-year-old man with leonine facies
A 66-year-old man was referred to our dermatology clinic for a 6-year history of a progressive pruritic rash, refractory to ...
Cure Today24 天
Follicular Lymphoma
Despite being declared cancer-free after initial treatment, I grapple with survivor's guilt, questioning why my lymphoma responded to therapy while others did not. When I started receiving treatment ...
PMLive13 天
Bristol Myers Squibb granted EC approval for Breyanzi in follicular lymphoma
Bristol Myers Squibb (BMS) has received approval from the European Commission (EC) for its CD19-directed CAR T cell therapy ...
Pharmabiz11 天
Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat ...
Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan: Tokyo Thursday, March 20, 2025, 11:00 Hrs ...